Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Al18F-NOTA-FAP-2286
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Al18F-NOTA-FAP-2286 is a radiopharmaceutical PET imaging tracer targeting fibroblast activation protein-alpha (FAPα). It consists of the FAP-targeting peptide ligand FAP-2286 conjugated to the chelator NOTA and labeled with the radioisotope fluorine-18 via an aluminum fluoride ([Al18F]2+) complex. FAP is highly expressed in the cancer-associated fibroblasts (CAFs) of various solid tumors but has low expression in normal tissues, making it a high-contrast target for molecular imaging. This tracer was developed to overcome limitations of 68Ga-labeled analogs, such as the short half-life of Gallium-68, by utilizing the longer half-life and superior imaging characteristics of Fluorine-18. It is particularly being explored for imaging PSMA-negative or PSMA-resistant prostate cancer and other FAP-expressing malignancies.
- Other names
- 18F-AlF-NOTA-FAP-2286Al18F-FAP-2286Al-18F-FAP-2286Al 18F-FAP-2286[18F]AlF-NOTA-FAP-2286
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on Al18F-NOTA-FAP-2286.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Al18F-NOTA-FAP-2286.